Cerecor raises $26M in a downsized IPO to fund its depression pipeline

Baltimore biotech Cerecor ($CERCU) raised $26 million in an IPO to bankroll its work on treatments for depression, issuing warrants to bring in the cash it needs. Cerecor priced 4 million units at $6.50 apiece, with each unit including one share of common stock, one warrant to purchase another share and a second warrant redeemable for a half share. With the proceeds, Cerecor is advancing three therapies for major depressive disorder, with two in Phase II and another in preclinical development. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.